LLY (NYSE) - Eli Lilly and Company | Stock Price & Analysis
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US5324571083
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana. Web URL:
Classification
Market Cap in USD | 579,856m |
Sector | Healthcare |
Industry | Drug Manufacturers - General |
GiC SubIndustry | Pharmaceuticals |
TER | 0.00% |
IPO / Inception | 1978-01-13 |
Ratings
Fundamental | 5.18 |
Dividend | 8.24 |
Performance 5y | 9.20 |
Rel. Performance vs Sector | 2.66 |
Analysts | 4.14 |
Fair Price Total Ret. | 727.99 |
Fair Price DCF | todo |
Technical
Growth TTM | 61.17% |
CAGR 5y | 40.06% |
CAGR / Mean Drawdown | 6.32 |
Sharpe Ratio TTM | 1.95 |
Alpha vs SP500 TTM | 50.73 |
Beta vs SP500 5y weekly | 0.61 |
CAPM | 6.91% |
Average Daily Range 2m | 2.91% |
Reversal Oscillator | 33.57 |
Volatility GJR Garch 1y | 26.03% |
Price / SMA 50 | 2.14% |
Price / SMA 200 | 26.12% |
Current Volume | 2436.7k |
Average Volume 20d | 3472.3k |
Dividends
Yield TTM | 0.76% |
Yield on Cost 5y | 4.13% |
Dividends CAGR 5y | 11.74% |
Consistency of Dividends all time | 99.7% |